Neoantigen-reactive CD8+ T cell engagement marks exceptional survivors of pancreatic cancer
Pancreatic cancer (PC) is largely refractory to immune checkpoint blockade (ICB), although homologous recombination-deficient (HRD) tumors may derive benefit. In the POLAR trial of maintenance pembrolizumab plus olaparib after platinum-based chemotherapy for metastatic PC, responses remained heterogeneous. To define determinants of productive antitumor immunity, we integrated longitudinal blood…
We haven't written up this one. bioRxiv has the full story — the link below goes straight to it.
